Loading... Please wait...

Our Newsletter


AP24534 (Ponatinib) | Abl, Src, FGFR, VEGFR inhibitor

  • AP24534 (Ponatinib).jpg
  • AP24534 (Ponatinib), 400x400px, png
Price:
$109.00
Catalog #:
C2724-5
Quantity:


Product Description

Ponatinib (AP24534) is a imidazopyridine-based pan-inhibitor of the kinases Abl, Abl(T315I), and other clinically important Abl kinase domain mutants at potencies of 0.37 nM, 2.0 nM, and 0.30-0.44 nM, respectively. Ponatinib also potently inhibits Src, VEGFR, FGFR, and PDGFR at 5.4, 1.5, 22, and 1.1 nM, respectively, while being >1000-fold selective over IGF-1R, Aurora A, andCDK2/Cyclin E. [1] In contrast to first- (imatinib) and second-line therapies (nilotinib, dasatinib) for CML, Ponatinib shows inhibition against the T31I mutant of Bcr-Abl.

In a panel of leukemic cell lines containing activating mutations in Flt3, Kit, or activating fusions of FGFR, PDGFRa, EOL1, and KG-1, Ponatinib inhibited phosphorylation of all four receptor tyrosine kinases in a dose dependent manner with IC50 values between 0.3 and 20 nM. [2] Apoptotic induction is believed to be the mechanism by which Ponatinib inhibits FLT3-ITD to in turn inhibit MV4-11 cell viability. [2]


Technical information:

Chemical Formula:   C29H27F3N6O
CAS #:   943319-70-8
Molecular Weight:   532.57
Purity:   >98%
Appearance:   White
Chemical Name:   3-(2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
Solubility:   Up to 100 mM in DMSO
Synonyms:   AP-24534, AP24534, Ponatinib

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


Reference:

1. O'Hare et al., AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Res. 2009, 16(5), 401-412. Pubmed ID: 19878872
2. Gozgit et al., Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol. Cancer. Ther. 2011, 10, 1028-1035. Pubmed ID: 21482694

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the AP24534 (Ponatinib) | Abl, Src, FGFR, VEGFR inhibitor to your wish list.

You Recently Viewed...